Among modern cardiovascular drugs, amlodipine preparations occupy a significant place for the treatment of both arterial hypertension (AH) and coronary heart disease (CHD). The main merit in this belongs to Norvasc® (amlodipine besylate). According to the PIFAGOR III pharmacoepidemiological study, the proportion of amlodipine in the structure of antihypertensive drugs (AHP) taken by patients with hypertension reaches 15%.